136 related articles for article (PubMed ID: 29733561)
1. [Ketamine administration in case of severe, therapy resistant depressed patient, case report].
Morvai S; Nagy AI; Bálint-Szöllősi A; Móré EC; Berecz R; Frecska E
Ideggyogy Sz; 2016 Nov; 69(11-12):421-425. PubMed ID: 29733561
[TBL] [Abstract][Full Text] [Related]
2. Repeat-dose ketamine augmentation for treatment-resistant depression with chronic suicidal ideation: A randomized, double blind, placebo controlled trial.
Ionescu DF; Bentley KH; Eikermann M; Taylor N; Akeju O; Swee MB; Pavone KJ; Petrie SR; Dording C; Mischoulon D; Alpert JE; Brown EN; Baer L; Nock MK; Fava M; Cusin C
J Affect Disord; 2019 Jan; 243():516-524. PubMed ID: 30286416
[TBL] [Abstract][Full Text] [Related]
3. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate CA; Singh JB; Carlson PJ; Brutsche NE; Ameli R; Luckenbaugh DA; Charney DS; Manji HK
Arch Gen Psychiatry; 2006 Aug; 63(8):856-64. PubMed ID: 16894061
[TBL] [Abstract][Full Text] [Related]
4. Effect of baseline anxious depression on initial and sustained antidepressant response to ketamine.
Ionescu DF; Luckenbaugh DA; Niciu MJ; Richards EM; Slonena EE; Vande Voort JL; Brutsche NE; Zarate CA
J Clin Psychiatry; 2014 Sep; 75(9):e932-8. PubMed ID: 25295436
[TBL] [Abstract][Full Text] [Related]
5. Repeated intravenous ketamine therapy in a patient with treatment-resistant major depression.
Liebrenz M; Stohler R; Borgeat A
World J Biol Psychiatry; 2009; 10(4 Pt 2):640-3. PubMed ID: 17853274
[TBL] [Abstract][Full Text] [Related]
6. Single i.v. ketamine augmentation of newly initiated escitalopram for major depression: results from a randomized, placebo-controlled 4-week study.
Hu YD; Xiang YT; Fang JX; Zu S; Sha S; Shi H; Ungvari GS; Correll CU; Chiu HF; Xue Y; Tian TF; Wu AS; Ma X; Wang G
Psychol Med; 2016 Feb; 46(3):623-35. PubMed ID: 26478208
[TBL] [Abstract][Full Text] [Related]
7. Comparison of racemic ketamine and S-ketamine in treatment-resistant major depression: report of two cases.
Paul R; Schaaff N; Padberg F; Möller HJ; Frodl T
World J Biol Psychiatry; 2009; 10(3):241-4. PubMed ID: 19224412
[TBL] [Abstract][Full Text] [Related]
8. Neurocognitive effects of ketamine and association with antidepressant response in individuals with treatment-resistant depression: a randomized controlled trial.
Murrough JW; Burdick KE; Levitch CF; Perez AM; Brallier JW; Chang LC; Foulkes A; Charney DS; Mathew SJ; Iosifescu DV
Neuropsychopharmacology; 2015 Mar; 40(5):1084-90. PubMed ID: 25374095
[TBL] [Abstract][Full Text] [Related]
9. KETAMINE FOR TREATMENT-RESISTANT UNIPOLAR AND BIPOLAR MAJOR DEPRESSION: CRITICAL REVIEW AND IMPLICATIONS FOR CLINICAL PRACTICE.
Bobo WV; Vande Voort JL; Croarkin PE; Leung JG; Tye SJ; Frye MA
Depress Anxiety; 2016 Aug; 33(8):698-710. PubMed ID: 27062450
[TBL] [Abstract][Full Text] [Related]
10. Ketamine Alleviates Depressive Symptoms in Patients Undergoing Intracranial Tumor Resection: A Randomized Controlled Trial.
Zhou Y; Sun W; Zhang G; Wang A; Lin S; Chan MTV; Peng Y; Wang G; Han R
Anesth Analg; 2021 Dec; 133(6):1588-1597. PubMed ID: 34633992
[TBL] [Abstract][Full Text] [Related]
11. Intravenous ketamine therapy in a patient with a treatment-resistant major depression.
Liebrenz M; Borgeat A; Leisinger R; Stohler R
Swiss Med Wkly; 2007 Apr; 137(15-16):234-6. PubMed ID: 17525879
[TBL] [Abstract][Full Text] [Related]
12. Comparing the actions of lanicemine and ketamine in depression: key role of the anterior cingulate.
Downey D; Dutta A; McKie S; Dawson GR; Dourish CT; Craig K; Smith MA; McCarthy DJ; Harmer CJ; Goodwin GM; Williams S; Deakin JF
Eur Neuropsychopharmacol; 2016 Jun; 26(6):994-1003. PubMed ID: 27133029
[TBL] [Abstract][Full Text] [Related]
13. A Double-Blind, Randomized, Placebo-Controlled, Dose-Frequency Study of Intravenous Ketamine in Patients With Treatment-Resistant Depression.
Singh JB; Fedgchin M; Daly EJ; De Boer P; Cooper K; Lim P; Pinter C; Murrough JW; Sanacora G; Shelton RC; Kurian B; Winokur A; Fava M; Manji H; Drevets WC; Van Nueten L
Am J Psychiatry; 2016 Aug; 173(8):816-26. PubMed ID: 27056608
[TBL] [Abstract][Full Text] [Related]
14. Novel Augmentation Strategies in Major Depression.
Martiny K
Dan Med J; 2017 Apr; 64(4):. PubMed ID: 28385173
[TBL] [Abstract][Full Text] [Related]
15. The use of ketamine in electroconvulsive therapy.
Kucia K; Merk W
Psychiatr Pol; 2015; 49(6):1255-63. PubMed ID: 26909400
[TBL] [Abstract][Full Text] [Related]
16. Synaptic potentiation and rapid antidepressant response to ketamine in treatment-resistant major depression: A replication study.
Nugent AC; Wills KE; Gilbert JR; Zarate CA
Psychiatry Res Neuroimaging; 2019 Jan; 283():64-66. PubMed ID: 30551012
[TBL] [Abstract][Full Text] [Related]
17. Mood and pain responses to repeat dose intramuscular ketamine in a depressed patient with advanced cancer.
Zanicotti CG; Perez D; Glue P
J Palliat Med; 2012 Apr; 15(4):400-3. PubMed ID: 22468772
[TBL] [Abstract][Full Text] [Related]
18. Is off-label repeat prescription of ketamine as a rapid antidepressant safe? Controversies, ethical concerns, and legal implications.
Zhang MW; Harris KM; Ho RC
BMC Med Ethics; 2016 Jan; 17():4. PubMed ID: 26768892
[TBL] [Abstract][Full Text] [Related]
19. [Ketamine for treatment of acute depression].
Hjerrild S; Bjerre J; Pedersen RH; Videbech P
Ugeskr Laeger; 2013 Sep; 175(37):2090-3. PubMed ID: 24011203
[TBL] [Abstract][Full Text] [Related]
20. Ketamine's effectiveness in unipolar versus bipolar depression.
Fond G; Boyer L
Psychopharmacology (Berl); 2014 Nov; 231(22):4417-8. PubMed ID: 25315362
[No Abstract] [Full Text] [Related]
[Next] [New Search]
